Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.

Internal and emergency medicine - 1 Jun 2010

Vannucchi Alessandro M

Abstract excerpt

The classic myeloproliferative neoplasms (MPNs) include polycythemia vera and essential thrombocythemia; their molecular basis has been described only recently with the demonstration of recurrent mutations in JAK2 or MPL. While life expectancy may not be significantly shortened, arterial and veno...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aspirin
Share to Janus Kinase 2
Share to Leukocytosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Platelet Aggregation Inhibitors

Share to Polycythemia Vera

Share to Thrombocythemia, Essential

Share to Thrombosis

Source

Identifiers

PMID: 19789961
DOI: 10.1007/s11739-009-0319-3

Genes

JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19789961-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.PMID 19789961Read ↗

Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.Semantic proximity Read ↗

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Thrombocytosis and thrombosis.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

It is time to change thrombosis risk assessment for PV and ET?Semantic proximity Read ↗

[Vascular complications of essential thrombocythemia].Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemiaSemantic proximity Read ↗

Molecular biomarkers of thrombosis in myeloproliferative neoplasms.Semantic proximity Read ↗

Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.